Chinese Journal of Clinical Anatomy ›› 2021, Vol. 39 ›› Issue (5): 563-568.doi: 10.13418/j.issn.1001-165x.2021.05.012

Previous Articles     Next Articles

Effect of irbesartan on insulin resistance IRS-1/PI3K/GLUT4 signaling pathway in rats with hypertension and type 2 diabetes mellitus

Liu Li1, Luo Peng1, Zhou Tiantian1, Li Yan2, Xie Hongyan2, Lv De3   

  1. 1. Department of Endocrinology, Pangang Group General Hospital, Panzhihua 617000, Sichuan Province, China;  2. Base Office of Affiliated Hospital of  Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China;  3. Department of Endocrinology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
  • Received:2020-07-07 Online:2021-09-25 Published:2021-09-29

Abstract: Objective    To investigate the effect of irbesartan on insulin resistance in hypertensive rats with type 2 diabetes mellitus (T2DM).    Methods    Spontaneously hypertensive rats (SHR) were randomly divided into a model group, an irbesartan low dose group and an irbesartan high dose group. Normal rats were used as control group. Irbesartan was administered daily at 30 and 60 mg/kg in the low and high dose groups, while the same amount of normal saline was performed in the control group and model group. Systolic blood pressure (SBP), fasting blood glucose (FBG), insulin resistance model evaluation index (HOMA-IR), insulin receptor substrate -1 (IRS-1), phosphatidylinositol (-3) kinase P85 subunit (PI3Kp85), protein kinase B (AKT), phosphorylated protein (p-AKT), and glucose transporter 4 (GLUT4) were measured in rats.   Results Compared with the control group, SBP, FBG, FINS and HOMA-IR in the model group significantly increased (P<0.05), while IRS-1, PI3Kp85, P-Akt and GLUT4 significantly decreased (P<0.05). Compared with the model group, the above indicators were reversed in both the low and high dose irbesartan groups(P<0.05). Conclusions     Irbesartan can improve insulin resistance in T2DM rats with hypertension through IRS-1/PI3K/GLUT4 signaling pathway.

Key words: Irbesartan, High blood pressure; ,  , Type 2 diabetes; ,  , Insulin resistance; ,  , IRS-1/PI3K/GLUT4 signaling pathway

CLC Number: